Product Description
NG-350A is being developed by PsiOxus for the treatment of patients with Epithelial Tumor and Metastatic Cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05165433?term=NG-350A&draw=2&rank=1)
Mechanisms of Action: CD40 Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Akamis Bio
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Colorectal Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| FORTRESS | P1 |
Recruiting |
Colorectal Cancer |
2026-02-28 |
23% |
2025-05-07 |
|
| FORTIFY | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2025-03-17 |
23% |
2024-08-10 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/06/2025 |
News Article |
Akamis Bio Broadens Leadership Team with Key Executive Appointments |
|
04/03/2025 |
News Article |
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer |
|
12/17/2024 |
News Article |
Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership |
|
10/23/2024 |
News Article |
Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload |